CORDIS · 952346 · H2020
RareBoost Boosting the Rare Disease research and innovation capacity of the Izmir Biomedicine and Genome Center
Coordinator: IZMIR BIYOTIP VE GENOM MERKEZI (TR)
Although diseases afflicting less than 1 person in 2000 are defined as rare diseases, the approx. 6000 different rare diseases together cause, nonetheless, a major burden on human wellbeing and the health systems. Over 90% of all rare diseases are currently without approved treatment and approx. 80% of them are genetic in origin. However, the research on rare diseases and the development of new diagnostic and therapeutic approaches is often hampered by limited resources, including patient material and biological models. The frequency of rare diseases increases in populations with a high frequ…
About Horizon 2020 (2014–2020)
Horizon 2020 was the EU's flagship research and innovation programme for 2014–2020, with a budget of around €77 billion. It bundled FP7's strands with the EIT and the Competitiveness and Innovation Programme, introduced a stronger societal-challenge orientation, and pushed the funding logic toward closer-to-market innovation. New calls closed in 2020 but funded projects continued through 2024.
EU contribution: €2.5M awarded to the consortium. The project runs over approximately 7 years from 2020-10-01 to 2027-09-30.
Full record on CORDIS — partners, deliverables, publications, news.
Open on cordis.europa.eu → Grant DOI ↗More from TR
see all →- CoCirculation3 — CO-FUNDED Brain Circulation 3101179377 · HORIZON · €9.6M
- TEAM-NANO — Teaming for Capacity Development and Synergies in Micro-nanofabrication and Flexible Electronics for Widespread Impact101136388 · HORIZON · €9.0M
- SHEREC — SAFE, HEALTHY AND ENVIRONMENTAL SHIP RECYCLING101136056 · HORIZON · €8.0M
- CoCirculation2 — CO-FUNDED Brain Circulation Scheme 2801509 · H2020 · €6.2M
- DIAMETER — Demonstration of a sustainable circular-by-design manufacturing system based on additive manufacturing101177422 · HORIZON · €6.0M
- HSMonitor — Pre-commercial Procurement of innovative ICT-enabled monitoring to improve health status and optimise hypertension care856698 · H2020 · €5.9M
Other H2020 projects
see all →- EUROfusion — Implementation of activities described in the Roadmap to Fusion during Horizon 2020 through a Joint programme of the members of the EUROfusion consortium633053 · DE · €678.8M
- H2020 — COST at a turning point: A unique framework for pan-European ST cooperation as clear demonstration of European values681463 · BE · €178.2M
- HBP SGA3 — Human Brain Project Specific Grant Agreement 3945539 · BE · €150.0M
- COVID-19 VACCINES — PROPOSAL FOR FUNDING RESEARCH DEVELOPMENT AND MANUFACTURING OF VACCINE AGAINST COVID-19101018100 · NO · €100.0M
- UNITE4TB — ACADEMIA AND INDUSTRY UNITED INNOVATION AND TREATMENT FOR TUBERCULOSIS101007873 · NL · €92.5M
- ERA4TB — EUROPEAN REGIMEN ACCELERATOR FOR TUBERCULOSIS853989 · ES · €89.8M
Frequently asked questions
- Who funds this research project?
- This project is funded by the European Union through the Horizon 2020 (2014–2020) programme, under the CSA funding scheme.
- What is the EU contribution?
- The European Commission contributes €2.5M toward a total project budget of €2.5M.
- Which EU programme funds it?
- The project is funded under Horizon 2020 (2014–2020), call H2020-WIDESPREAD-2018-2020.
- Who coordinates the project?
- The project is coordinated by IZMIR BIYOTIP VE GENOM MERKEZI (TR).
- What is the project timeline?
- The project runs from 2020-10-01 to 2027-09-30 — approximately 7 years.
- Where can I find the full project record?
- The complete record — partners, deliverables, publications and news — is published on CORDIS under project ID 952346.